Farmington, CT – According to filings with the U.S. Securities and Exchange Commission, Rallybio Holdings is raising $130,000,000.00 in new funding. Sources indicate as part of senior management Chief Executive Officer, Martin Mackay played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Rallybio Holdings

Rallybio is a privately-held, development-stage biotechnology company focused on bringing life-transforming medicines to patients with devastating and rare disorders. The company is built around a seasoned team of biopharma industry leaders with extensive research, development, and business experience. With offices located in the University of Connecticut’s Technology Incubation Program campus, Rallybio is continuing its extensive drug acquisition and development activities.  The company has built an impressive team uniquely capable of effectively identifying, attaining and developing assets that are aligned with Rallybio’s mission.  The team is working tenaciously to continue expanding and advancing its pipeline of therapies that will transform the lives of patients with severe and rare disorders.

To learn more about Rallybio Holdings, visit http://rallybio.com/

Contact:
Martin Mackay, Chief Executive Officer
203-859-3820
mmackay@rallybio.com

SOURCE: http://www.intelligence360.io
Copyright (c) 2020 SI360 Inc. All rights reserved